[Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example of molecules Sema4D and CD72].

I Y Danchenko Tatiana V Baidina Elena Kuklina T N Trushnikova I V Nekrasova

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)

The use of SemaD as a target in the treatment of RRMS is scientifically substantiated. In case of a positive decision on the use of anti-Sema4D drugs, it will be necessary to take into account the effects of semaphorin not only in the central nervous system, but also in the immune system of patients with RRMS.

Keyphrases

multiple sclerosis
white matter
cerebrospinal fluid
decision making
combination therapy
replacement therapy